Reviewed listing: NASDAQ:VCEL · Analysis dated Oct 13, 2026
It has not been confirmed whether the basis of this analysis still holds today. Read it as a dated earlier assessment; it does not establish a current buying opportunity.
How does the company make money?
Vericel makes treatments from patients’ own cells for damaged knee cartilage and severe skin burns. The company also markets NexoBrid, a product for removing dead tissue after burns.
What supports the business?
Vericel is selling more treatments and now retains significantly more cash after investments; however, lower investment and faster collections also contribute. A high balance of cash and securities with no bank borrowings strengthens financial resilience.
What could improve?
If Vericel attracts more doctors to its treatments and makes better use of its production capacity, profits could grow faster than revenue. Approval of MACI in the UK and additional government contracts for NexoBrid would be further opportunities, but are not guaranteed.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
40.62 USD appear expensive despite the strong business: the implied value of all shares, calculated approximately, equals around 86 times the company’s earnings over the latest twelve months. The price therefore assumes substantial further earnings improvement.
What is the main risk?
Vericel depends heavily on its MACI knee cartilage treatment and insurers' payment for it. Weaker demand or less favorable reimbursement could weigh on its still-thin profit margin and demanding stock price.
What is the overall assessment?
Strong specialty therapeutics business with demonstrable improvement, but at 40.62 USD there is not yet a compelling balance between price and risks. Watch: the share price requires sustainable earnings increases that are not substantiated by revenue growth and adjusted results alone.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign in